Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. 1991

J el-On, and A Sulitzeanu, and L F Schnur
Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.

Cutaneous lesions caused by Leishmania major in BALB/c mice were cured completely when treated topically with an ointment comprising 15% paromomycin sulphate and 1-2% methylbenzethonium chloride ointment in soft white paraffin twice daily for 10 days. No parasites were detected in tissue smears or in cultures from treated cutaneous lesions. Re-developing lesions, considered to be resulting from the migration of parasites from internal organs, showed almost the same response to topical treatment. Promastigotes of the virulent clone 121 of L. major LRC-L137 which were exposed to 100 micrograms ml-1 of paromomycin in RPMI medium at 28 degrees C developed resistance to the drug over 10 passages of exposure. Enzyme analysis of susceptible and resistant promastigotes of this clone showed no differences with regard to their profiles based on 11 enzymes.

UI MeSH Term Description Entries
D007895 Leishmania tropica A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects humans and rodents. This taxonomic complex includes species which cause a disease called Oriental sore which is a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World. Leishmania (Leishmania) tropica,Leishmania tropica minor,Leishmania leishmania tropica,Leishmania tropicas
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D010303 Paromomycin An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES. Aminosidine,Catenulin,Estomycin,Hydroxymycin,Neomycin E,Gabbromycin,Humatin,Paramomycin,Paromomycin I,Paromomycin Phosphate,Paromomycin Sulfate,Paromomycin Sulfate (1:1),Paromomycin Sulfate (2:5),Paromomycin, beta-D-Glucopyranosyl-Isomer,Paromomycin, beta D Glucopyranosyl Isomer,beta-D-Glucopyranosyl-Isomer Paromomycin
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000891 Anti-Infective Agents, Local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. Anti-Infective Agents, Topical,Antiseptic,Antiseptics,Microbicides, Local,Microbicides, Topical,Antiinfective Agents, Local,Antiinfective Agents, Topical,Local Anti-Infective Agents,Local Antiinfective Agents,Topical Anti-Infective Agents,Topical Antiinfective Agents,Agents, Local Anti-Infective,Agents, Local Antiinfective,Agents, Topical Anti-Infective,Agents, Topical Antiinfective,Anti Infective Agents, Local,Anti Infective Agents, Topical,Local Anti Infective Agents,Local Microbicides,Topical Anti Infective Agents,Topical Microbicides
D001558 Benzethonium Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade. Bencetonium Chloride,Benzethonium Chloride,Formula Magic,Hyamine 1622,Orchid Fresh II,Phemeride,Phemerol,Phemethryn,Puri-Clens,Quatrachlor,Solamin,Chloride, Bencetonium,Chloride, Benzethonium,Magic, Formula,Puri Clens,PuriClens
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J el-On, and A Sulitzeanu, and L F Schnur
June 1987, Journal of the American Academy of Dermatology,
J el-On, and A Sulitzeanu, and L F Schnur
November 1986, The American journal of tropical medicine and hygiene,
J el-On, and A Sulitzeanu, and L F Schnur
September 1985, British medical journal (Clinical research ed.),
J el-On, and A Sulitzeanu, and L F Schnur
August 1999, Biochemical Society transactions,
J el-On, and A Sulitzeanu, and L F Schnur
November 1981, Molecular and biochemical parasitology,
J el-On, and A Sulitzeanu, and L F Schnur
September 1985, The Journal of experimental medicine,
J el-On, and A Sulitzeanu, and L F Schnur
January 2020, Infectious disorders drug targets,
J el-On, and A Sulitzeanu, and L F Schnur
December 1982, Experimental parasitology,
J el-On, and A Sulitzeanu, and L F Schnur
August 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Copied contents to your clipboard!